Treatment of active rheumatoid arthritis with leflunomide: Two year follow up of a double blind, placebo controlled trial versus sulfasalazine

Annals of the Rheumatic Diseases

Volumn 60, Issue 10, 2001, Pages 913-923

  Scott, D L ^a   Smolen, J S ^b   Kalden, J R ^c   Van de Putte, L B A ^d   Larsen, A ^e   Kvien, T K ^f   Schattenkirchner, M ^g   Nash, P ^h   Oed, C ⁱ   Loew Friedrich, I ⁱ  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NORWEGIAN KNOWLEDGE CENTRE FOR THE HEALTH SERVICES   (Norway)

^f DIAKONHJEMMET HOSPITAL   (Norway)

^g UNIVERSITY OF MUNICH   (Germany)

^h NONE   (Australia)

ⁱ Aventis Pharma   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LEFLUNOMIDE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ALOPECIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CONFIDENCE INTERVALS; DISABILITY EVALUATION; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOXAZOLES; LOGISTIC MODELS; MALE; MIDDLE AGED; RHEUMATOID FACTOR; STATISTICS, NONPARAMETRIC; SULFASALAZINE; TREATMENT OUTCOME;

EID: 0034827629     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.60.10.913     Document Type: Article

References (46)

1. The bone and joint decade 2000-2010
2. Measurement of patient outcome in arthritis
3. Use of short-term efficacy/toxicity tradeoffs to select second-line drugs in rheumatoid arthritis: A meta-analysis of published clinical trials
4. Currently used second-line agents: Do they control the disease course?
5. Adverse drug reactions of DMARDs and DC-ARTs in rheumatoid arthritis
6. Effects of leflunomide on immune responses and models of inflammation
7. Leflunomide inhibits pyrimidine de novo sythesis in mitogen-stimulated T-lymphocytes from healthy humans
8. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: Results of a randomized, placebo-controlled, phase II study
9. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: A double-blind, randomised, multicentre trial
10. Treatment of active rheumatoid arthritis with leflunomide compared to placebo and methotrexate
11. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis
12. Mechanism of action of leflunomide in rheumatoid arthritis
13. Methotrexate and leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritis
14. Importance of ribonucleotide availability to proliferating T-lymphocytes from healthy humans
15. Leflunomide: Mode of action in the treatment of rheumatoid arthritis
16. Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-κB activation and gene expression
17. Leflunomide's active metabolite A77-1726 and its derivatives, the malononitrilamides, inhibit the generation of oxygen radicals in mononuclear phagocytes
18. Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: Findings in a prospective, randomized, double-blind clinical trial in fifteen patients
19. Exposure of T lymphocytes to leflumonide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue-inhibitor of metalloproteinases-1 over that of interleukin-1β and metalloproteinases
20. Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Findings in a prospective, randomized, double-blind, parallel-design clinical trial in thirty-nine patients at two centers
21. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind, placebo controlled study
22. Comparison of standard and alternative health assessment questionnaire scoring procedures for documenting functional outcomes in patients with rheumatoid arthritis
23. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films
24. Radiographic evaluation of rheumatoid arthritis in therapeutic trials
25. Criteria for clinically important changes in outcomes: Development, scoring and evaluation of rheumatoid arthritis patient and trial profiles
26. Minimum important difference between patients with rheumatoid arthritis: The patient's perspective
27. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis. Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial
28. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis
29. Second line (disease modifying) treatment in rheumatoid arthritis: Which drug for which patient?
30. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: Results of a co-operating clinics study
31. Intention-to-treat analysis of 200 patients with rheumatoid arthritis 12 years after random allocation to either sulfasalazine or penicillamine
32. Sulfasalazine treatment for rheumatoid arthritis: A metaanalysis of 15 randomized trials
33. Sulphasalazine: A safe, effective agent for prolonged control of rheumatoid arthritis. A comparison with sodium aurothiomalate
34. Long term treatment of rheumatoid arthritis with sulphasalazine, gold, or penicillamine: A comparison using life-table methods
35. Sulphasalazine in the treatment of rheumatoid arthritis
36. Australian Multicentre Clinical Trial Group Sulfasalazine in early rheumatoid arthritis
37. Anti-inflammatory analgesic drug responders and non-responders: A clinico-pharmacological study of flurbiprofen
38. Variations in responses to non-steroidal anti-inflammatory drugs
39. Variability in response to NSAID
40. Correlation of serologic indicators of inflammation with effectiveness of nonsteroidal antiinflammatory drug therapy in rheumatoid arthritis
41. Nonsteroidal antiinflammatory drugs in rheumatoid arthritis and osteoarthritis. Support for the concept of "responders" and "nonresponders"
42. Long-term course and outcome of functional capacity in rheumatoid arthritis: The effect of disease activity and radiologic damage over time
43. The acute phase and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome
44. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants
45. Effect of sulphasalazine on the radiological progression of rheumatoid arthritis
46. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis